Today’s Neuralink news highlights Neuralink, Elon Musk’s brain implant company, aims to generate at least $1 billion in annual revenue by 2031. The company plans to implant its neural chips in 20,000 people annually and operate five large clinics within six years. Neuralink is developing three implant versions: Telepathy for brain-machine communication, Blindsight to restore vision, and Deep to treat conditions like tremors and Parkinson’s disease. Regulatory approval for Telepathy is expected by 2029, with 2,000 surgeries annually and $100 million in revenue, followed by the launch of Blindsight in 2030, aiming for 10,000 surgeries and over $500 million in revenue. The company is valued at approximately $9 billion and has raised around $1.3 billion, including $650 million in its most recent funding round. Human trials began in 2024 after addressing prior FDA safety concerns, and currently, five paralyzed patients use Neuralink’s implant to control digital and physical devices through thought..
Neuralink Targets $1 Billion Revenue by 2031
